In pre-treatment patients withactive SLE (SLEDAI≥3), had low levels of IL-2 concentrations, increased IL-4, TNF-α, IFN - concentrations; decreased lympho T-CD4, NK CD56 count in comparison to those of healthy people (p<0, 001).